Biogen Inc. (BIIB)
BIIB Stock Price Chart
Explore Biogen Inc. interactive price chart. Choose custom timeframes to analyze BIIB price movements and trends.
BIIB Company Profile
Discover essential business fundamentals and corporate details for Biogen Inc. (BIIB) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - General
IPO Date
17 Sept 1991
Employees
7.61K
Website
https://www.biogen.comCEO
Christopher A. Viehbacher
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
BIIB Financial Timeline
Browse a chronological timeline of Biogen Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 29 Apr 2026
Upcoming earnings on 10 Feb 2026
Upcoming earnings on 29 Oct 2025
EPS estimate is $3.90, while revenue estimate is $2.34B.
Earnings released on 31 Jul 2025
EPS came in at $5.47 surpassing the estimated $3.90 by +40.26%, while revenue for the quarter reached $2.65B , beating expectations by +13.63%.
Earnings released on 1 May 2025
EPS came in at $3.02 surpassing the estimated $2.90 by +4.14%, while revenue for the quarter reached $2.43B , beating expectations by +8.81%.
Earnings released on 12 Feb 2025
EPS came in at $3.44 surpassing the estimated $3.43 by +0.29%, while revenue for the quarter reached $2.45B , beating expectations by +1.93%.
Earnings released on 30 Oct 2024
EPS came in at $4.08 surpassing the estimated $3.77 by +8.22%, while revenue for the quarter reached $2.47B , beating expectations by +1.29%.
Earnings released on 1 Aug 2024
EPS came in at $5.28 surpassing the estimated $4.07 by +29.73%, while revenue for the quarter reached $2.35B , missing expectations by -1.65%.
Earnings released on 24 Apr 2024
EPS came in at $3.67 surpassing the estimated $3.47 by +5.76%, while revenue for the quarter reached $2.20B , missing expectations by -4.71%.
Earnings released on 13 Feb 2024
EPS came in at $2.95 falling short of the estimated $3.16 by -6.65%, while revenue for the quarter reached $2.39B , missing expectations by -3.19%.
Earnings released on 8 Nov 2023
EPS came in at $4.36 surpassing the estimated $3.99 by +9.27%, while revenue for the quarter reached $2.53B , beating expectations by +5.88%.
Earnings released on 25 Jul 2023
EPS came in at $4.02 surpassing the estimated $3.77 by +6.63%, while revenue for the quarter reached $2.46B , beating expectations by +3.66%.
Earnings released on 25 Apr 2023
EPS came in at $3.40 surpassing the estimated $3.28 by +3.66%, while revenue for the quarter reached $2.46B , beating expectations by +5.17%.
Earnings released on 15 Feb 2023
EPS came in at $4.05 surpassing the estimated $3.48 by +16.38%, while revenue for the quarter reached $2.54B , beating expectations by +4.04%.
Earnings released on 25 Oct 2022
EPS came in at $4.77 surpassing the estimated $4.13 by +15.50%, while revenue for the quarter reached $2.51B , beating expectations by +1.60%.
Earnings released on 20 Jul 2022
EPS came in at $5.25 surpassing the estimated $4.06 by +29.31%, while revenue for the quarter reached $2.59B , beating expectations by +4.66%.
Earnings released on 3 May 2022
EPS came in at $3.62 falling short of the estimated $4.41 by -17.91%, while revenue for the quarter reached $2.53B , beating expectations by +1.28%.
Earnings released on 3 Feb 2022
EPS came in at $3.39 surpassing the estimated $3.32 by +2.11%, while revenue for the quarter reached $2.73B , beating expectations by +4.34%.
Earnings released on 20 Oct 2021
EPS came in at $4.77 surpassing the estimated $4.15 by +14.94%, while revenue for the quarter reached $2.78B , beating expectations by +4.07%.
Earnings released on 22 Jul 2021
EPS came in at $5.68 surpassing the estimated $4.57 by +24.29%, while revenue for the quarter reached $2.78B , beating expectations by +3.73%.
Earnings released on 22 Apr 2021
EPS came in at $5.34 surpassing the estimated $5.06 by +5.53%, while revenue for the quarter reached $2.69B , beating expectations by +1.09%.
Earnings released on 3 Feb 2021
EPS came in at $4.58 falling short of the estimated $4.93 by -7.10%, while revenue for the quarter reached $2.85B , missing expectations by -5.62%.
Earnings released on 21 Oct 2020
EPS came in at $8.84 surpassing the estimated $8.06 by +9.68%, while revenue for the quarter reached $3.38B , beating expectations by +216.00%.
BIIB Stock Performance
Access detailed BIIB performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.